Azadiradione regulates Heat Shock Factor 1 function by interacting with its DNA-binding domain independent of the oligomerization domain
Anirban MannaiD, Papri BasakiD, Chirantan MajumderiD, Nilanjana HazraiD, Satyajit HalderiD, Kuladip JanaiD, Jayanta MukhopadhyayiD, Subhash Chandra MandaliD, Mahadeb PaliD
Abstract
Heat shock factor 1 (HSF1) masters cellular proteostasis under stress by upregulating the expression of molecular chaperones that help refold or degrade the misfolded proteins. HSF1 activation involves a monomer-to-oligomer transition and binding to its recognition sequence, the heat shock elements (HSEs) on its target gene promoters. HSF1 activity declines with age as well as in neurodegenerative disorders (NDs) such as Parkinsons disease, highlighting the need for strategies to restore its function. Azadiradione (AZD), a limonoid isolated from Azadirachta indica seeds, directly activates HSF1 in cellular and preclinical ND models, unlike other small-molecule activators reported elsewhere. We investigated the molecular basis of AZD-mediated HSF1 activation using purified variants of this protein including those without its oligomerization and transactivation domain. Fluorescence polarization and dynamic light scattering assays revealed that AZD promotes the oligomerization of monomeric HSF1 to enhance its HSE-binding affinity by engaging with its DNA-binding domain (DBD). The oligomerization domain known to be required for stress-induced activation, appears redundant in AZD-mediated activation. Furthermore, evidence suggests AZD-induced conformational alterations in the HSE facilitate its binding to the HSF1 monomer. Notably, AZD reduces the DNA-binding ability of pre-assembled oligomeric HSF1 by triggering its amyloid-like aggregation. This finding also highlighted a potential anticancer effect of AZD, as cancer cells heavily depend on this HSF1 population for rapid proliferation and survival. Overall, these findings offer novel insights into the functional regulation of HSF1 and suggest a framework for developing small-molecule HSF1 activators with therapeutic potential for protein conformation disorders.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 48%
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- HSF1 Activator Azadiradione Ameliorates Parkinson Disease and Extends Lifespan in Preclinical Models: Analysis of Underlying Molecular Mechanism
HOSSAINOOR RAHAMAN SARENG, Naibedya Dutta, … Mahadeb Pal·bioRxiv·Apr 9, 2025
- Epoxyazadiradione ameliorates Parkinson's disease by upregulating heat shock factor 1 and protein degradation pathways in mice.
Shivani Chandel, Naibedya Dutta, … Mahadeb Pal·bioRxiv·Dec 11, 2025
- Molecular mechanism of attenuation of heat shock transcription factor 1 activity
Szymon W. Kmiecik, Laura Le Breton, Matthias P. Mayer·The EMBO JournalPeer-reviewed·Jun 3, 2020
- Hsf1 is SUMOylated in the activated trimeric state
S. W. Kmiecik, K. Drzewicka, … M. P. Mayer·bioRxiv·Oct 5, 2020
- AKT1 mediates multiple phosphorylation events that functionally promote HSF1 activation
W.-C. Lu, R. Omari, … R. L. Carpenter·The FEBS JournalPeer-reviewed·Feb 11, 2022
- HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
T. Kijima, T. L. Prince, … L. Neckers·bioRxiv·Mar 2, 2018